MAPT and Alzheimer disease: To test the hypothesis that the reduction of KIF5B alone can decrease tau accumulation, neurodegeneration, and memory impairment, we partially reduced the levels of KIF5B in P301S tau mutant mice (P301S), a mouse model of AD and FTPD-17, which develops extensive tau pathology throughout the nervous system with high accumulation of phospho tau filaments resembling those of human tauopathies (Allen et al., 2002).